Participated · Series A · Jan 2025

FIZE Medical develops the FIZE kUO®, a commercially available system that provides real-time digital monitoring to support precision fluid management for critically ill patients. The company positions its platform as enabling earlier intervention through continuous monitoring and AI-driven data insights. FIZE is pursuing expanded commercial adoption in the U.S., Europe and Japan while also investing in next-generation AI capabilities. It plans to increase clinical validation studies within leading hospitals to build evidence for its approach. Financially, the company recently increased its Series A financing to $36 million following a $6 million warrant exercise by existing investors. FIZE emphasizes ongoing innovation and clinical evidence generation as central to its growth strategy.

Led · Equity · Aug 2024

DreaMed Diabetes is an Israeli startup (Tel Aviv) that develops AI-driven solutions for diabetes care and management. Its flagship product, the endo.digital platform, uses artificial intelligence to generate personalized recommendations for insulin treatment to help healthcare providers optimize care. The company was founded in 2014 by Prof. Moshe Philip, Eran Atlas, Prof. Revital Nimri, and Ido Muller. DreaMed has agreements and partnerships with organizations including Abbott and Yale New Haven Health. With the newly raised funds, the company plans to expand operations in the U.S., advance its platform, grow the team, scale efforts, and enhance its technology. The articles do not disclose revenue or user metrics. DreaMed Diabetes is a Petah Tikva, Israel-based developer of diabetes treatment and management solutions that use algorithms and decision-support tools to optimize intensive insulin therapy for people with Type 1 and Type 2 diabetes. Founded in 2014 and led by CEO Eran Atlas and CCO Steve Bubrick, the company builds products aimed at personalized insulin treatment. Its first product, GlucoSitter™, was developed for closed-loop insulin therapy and was licensed to Medtronic. The company’s latest product, Advisor™, is a decision-support technology platform that determines optimal patient-specific insulin treatment plans to achieve balanced glucose levels. Advisor uses event-driven machine learning and logic to process personalized parameters such as insulin delivery data, glucose readings, and meal data. DreaMed raised $3.3M and will use the funds for further development of Advisor. DreaMed Diabetes, founded in 2014 and based in Petah Tikva, Israel, develops diabetes treatment and management software centered on its MD-Logic Artificial Pancreas algorithm. Its flagship product, the CE‑approved GlucoSitter, is a fully automated closed‑loop system that links continuous glucose sensors to insulin pumps and directs insulin delivery via computerized control algorithms. The GlucoSitter has been tested in randomized, multicenter clinical trials on more than 220 patients and logged over 15,000 hours of operational use, with results published in leading journals including the New England Journal of Medicine. Additional development programs include insulin‑treatment profiling for clinics, patient decision‑support and educational apps, and automatic insulin delivery systems. The company positions future innovation around software and sophisticated algorithms to improve metabolic control and patient quality of life. Financially, DreaMed has entered a strategic commercial collaboration with Medtronic that includes product licensing and a minority investment.

Led · Equity · Apr 2024

EFA Technologies develops RevDx, a portable diagnostic blood lab that uses microscopy and AI to identify pathogens, analyze biomarkers and deliver rapid, accurate results including a full CBC from a single drop of blood. RevDx is designed to be portable, affordable and user-friendly, aiming to reduce costs and time while improving the doctor–patient relationship. The company packages multi-channel capabilities—automatic microscopy and bio-sensing readers—into a platform intended to support additional diagnostic applications and an ecosystem of image-processed algorithms. EFA holds CE certification and secured ANVISA approval for RevDx, enabling its market entry into Brazil and prompting exploration of other international markets. Financially, EFA announced it secured US$6.5 million in growth capital to accelerate product development, expand market reach and foster further innovation. The company is backed by a medical board including Nobel Laureate Prof. Aaron Ciechanover. Engineering for All is developing RevDx©, a digital diagnostic programmable lab-on-hand system that the article says can enable fully automated microscopy diagnostics and real-time disease mapping through a handheld, real-time multichannel solution. The device is described as portable and self-powered, with full CBC and parasitology capabilities, infectious-disease diagnosis, and features intended to enable precise and affordable test-treat-track treatment. The company is working on a functional prototype and has won several awards in Israel; it has also presented with delegations in India and Taiwan. Financially, the company raised $900k in seed funding. The investment came from eHealth Ventures, an Israeli digital-health technological incubator led by CEO Yoel Ezra. Engineering for All is based in Tel Aviv, Israel.

Led · Seed · Jun 2023

Qlog develops a Healthcare Operations Platform built within the healthcare ecosystem to create real-time, crowd-sourced data flow and visibility. The company specializes in crowd-sourced ERP and RTLS resource-management tools for hospitals and clinics. Its platform gives healthcare institution managers and stakeholders full data visibility to optimize equipment utilization and minimize medication and equipment loss and waste. The technology is positioned to improve operational efficiency and patient safety. Qlog is led by Founder and CEO Dr. Amit Lehavi. The company intends to use recent funding to support expansion of its international commercial activities in the US, UK and EU.

Led · Seed · Apr 2023

Identifai-Genetics is a Tel Aviv-based digital bioinformatics company developing AI-driven non-invasive fetal DNA sequencing solutions. The company offers early, risk-free detection of fetal genetic disorders using a maternal blood test. It was co-founded in 2021 by Shizim Innovation Center and is led by chairman Yossi Bornstein, CSO Prof. Noam Shomron, CTO Dr. Tom Rabinowitz and CEO Dr. Amir Beker. Identifai recently engaged HcFocus, founded by Dr. Susan Gross, who will serve as Chief Strategic Advisor; Dr. Gross has extensive experience in non-invasive prenatal screening and was formerly CMO of Natera. The company intends to use the new funding to expand operations and R&D efforts. To date, Identifai has raised over $6M in equity investments and R&D grants.